ÉRÉva Remenyik

Éva Remenyik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Éva Remenyik has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study

    by Krisztián Gáspár, L. Hunor Gergely, Balázs Jenei, Norbert Wikonkál, Ágnes Kinyó, Andrea Szegedi, Éva Remenyik, Norbert Kiss, Xiang Jin, Miklós Sárdy, et al.

    Hidradenitis suppurativa (HS) is a, chronic skin disease affecting up to 1% of the population in Europe. This study aims to assess the cost-of-illness of HS from a societal perspective in Hungary a...


  • Open Access

    A Rasch model analysis of two interpretations of ‘not relevant’ responses on the Dermatology Life Quality Index (DLQI)

    by Fanni Rencz, Ariel Z. Mitev, Ákos Szabó, Zsuzsanna Beretzky, Adrienn K. Poór, Péter Holló, Norbert Wikonkál, Miklós Sárdy, Sarolta Kárpáti, Andrea Szegedi, et al.

    Purpose: Eight of the ten items of the Dermatology Life Quality Index (DLQI) have a ‘not relevant’ response (NRR) option. There are two possible ways to interpret NRRs: they may be considered ‘not at all’ or missing responses. We aim to compare the measurement performance of the DLQI in psoriasis patients when NRRs are scored as ‘0’ (hereafter zero-scoring) and ‘missing’ (hereafter missing-scoring) using Rasch model analysis. Methods: Data of 425 patients with psoriasis from two earlier cross-sectional surveys were re-analysed. All patients completed the paper-based Hungarian version of the DLQI. A partial credit model was applied. The following model assumptions and measurement properties were tested: dimensionality, item fit, person reliability, order of response options and differential item functioning (DIF). Results: Principal component analysis of the residuals of the Rasch model confirmed the unidimensional structure of the DLQI. Person separation reliability indices were similar with zero-scoring (0.910) and missing-scoring (0.914) NRRs. With zero-scoring, items 6 (sport), 7 (working/studying) and 9 (sexual difficulties) suffered from item misfit and item-level disordering. With missing-scoring, no misfit was observed and only item 7 was illogically ordered. Six and three items showed DIF for gender and age, respectively, that were reduced to four and three by missing-scoring. Conclusions: Missing-scoring NRRs resulted in an improved measurement performance of the scale. DLQI scores of patients with at least one vs. no NRRs cannot be directly compared. Our findings provide further empirical support to the DLQI-R scoring modification that treats NRRs as missing and replaces them with the average score of the relevant items.


  • Open Access

    The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa

    by Alex Bató, Valentin Brodszky, L. Hunor Gergely, Krisztián Gáspár, Norbert Wikonkál, Ágnes Kinyó, Ákos Szabó, Zsuzsanna Beretzky, Andrea Szegedi, Éva Remenyik, et al.

    Purpose: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that affects up to 1% of the population in Europe. The EQ-5D is the most commonly used generic instrument for measuring health-related quality of life among HS patients. This study aims to compare the measurement properties of the two adult versions of EQ-5D (EQ-5D-3L and EQ-5D-5L) in patients with HS. Methods: We recruited 200 consecutive patients with HS (mean age 37 years, 38% severe or very severe HS) to participate in a multicentre cross-sectional survey. Patients completed the EQ-5D-3L, EQ-5D-5L, Dermatology Life Quality Index (DLQI) and Skindex-16 questionnaires. Results: More than twice as many different health state profiles occurred in the EQ-5D-5L compared to the EQ-5D-3L (101 vs. 43). A significant reduction in ceiling effect was found for the mobility, self-care and usual activities dimensions. A good agreement was established between the EQ-5D-3L and EQ-5D-5L with an intraclass correlation coefficient of 0.872 (95% CI 0.830–0.903; p < 0.001) that was confirmed by a Bland-Altman plot. EQ-5D-5L improved both the absolute and relative informativity in all dimensions except for anxiety/depression. EQ-5D-3L and EQ-5D-5L demonstrated similar convergent validity with DLQI and Skindex-16. EQ-5D-5L was able to better discriminate between known groups of patients based on the number of comorbidities and disease severity (HS-Physician's Global Assessment). Conclusion: In patients with HS, the EQ-5D-5L outperformed the EQ-5D-3L in feasibility, ceiling effects, informativity and known-groups validity for many important clinical characteristics. We recommend using the EQ-5D-5L in HS patients across various settings, including clinical care, research and economic evaluations.


  • Open Access

    Validity of EQ‐5D‐5L, Skindex‐16, DLQI and DLQI‐R in patients with hidradenitis suppurativa

    by L.H. Gergely, K. Gáspár, V. Brodszky, Á. Kinyó, A. Szegedi, É. Remenyik, N.F. Kiss, A. Bató, M. Péntek, L. Gulácsi, et al.

    Background: Numerous generic, skin‐ and disease‐specific health‐related quality of life (HRQoL) measures are available for patients with hidradenitis suppurativa (HS). Yet, robust psychometric evidence is lacking in many aspects of these outcome measures.Objectives: We sought to determine convergent and known‐groups validity of multiple generic and skin‐specific HRQoL measures and to identify predictors of impaired HRQoL in patients with HS.Methods: Between 2017 and 2019, a multicentre cross‐sectional study was carried out involving 200 consecutive HS patients. HRQoL outcomes included the EQ‐5D‐5L, EQ visual analogue scale (EQ VAS), Skindex‐16, Dermatology Life Quality Index (DLQI) and DLQI‐Relevant (DLQI‐R). Disease severity was graded by HS‐Physician’s Global Assessment (HS‐PGA) scale and the Modified Sartorius scale (MSS).Results: Overall, 77%, 56%, 51%, 46% and 28% reported problems in the pain/discomfort, usual activities, anxiety/depression, mobility and self‐care dimensions of EQ‐5D‐5L. Mean ± SD EQ VAS, DLQI and DLQI‐R scores were 64.29 ± 22.68, 11.75 ± 8.11 and 12.19 ± 8.33, respectively. Skindex‐16 responses indicated that the emotional burden of HS (64.55 ± 29.28) far exceeded those of functioning (49.40 ± 34.70) and physical symptoms (46.74 ± 29.36). EQ‐5D‐5L, EQ VAS, DLQI, DLQI‐R and Skindex‐16 total scores had moderate or strong correlations with each other (range: |0.487| to |0.993|), weak or moderate correlations with HS‐PGA (|0.350| to |0.433|) and weak correlations with MSS (|0.324| to |0.389|). DLQI‐R slightly outperformed DLQI both in terms of convergent and known‐groups validity. Being female, lower education level, more severe disease and genital involvement were associated with worse HRQoL (P < 0.05).Conclusion: This study provides high‐quality evidence that among skin‐specific outcomes, the DLQI, DLQI‐R and Skindex‐16, and among generic instruments, the EQ‐5D‐5L are suitable to be used in HS patients. In future research, we recommend the use of existing well‐validated HRQoL tools instead of developing new measures for each study. The development of composite measures that combine physician‐ and patient‐reported outcomes is not supported by evidence in HS.[Correction added on 25 July 2020, after first online publication: in the Abstract section, the ± signs were missing and have been added to this version.]


  • Dermatology Life Quality Index (DLQI) score bands are applicable to DLQI‐Relevant (DLQI‐R) scoring

    by F. Rencz, L.H. Gergely, N. Wikonkál, K. Gáspár, M. Péntek, L. Gulácsi, B. Tamási, A.K. Poór, Á. Kinyó, G. Bali, et al.

    DLQI‐Relevant (DLQI‐R) is a recently developed scoring modification of the Dermatology Life Quality Index (DLQI) that improved convergent validity, discriminatory power and responsiveness of the questionnaire.


  • Open Access

    DLQI‐R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea

    by F. Rencz, L. Gulácsi, M. Péntek, A. Szegedi, É. Remenyik, Z. Bata‐Csörgő, G. Bali, B. Hidvégi, B. Tamási, A.K. Poór, et al.

    Background The Dermatology Life Quality Index (DLQI) rates ‘not relevant’ responses (NRRs) as the item on the questionnaire having no impact on the patients’ lives at all. The DLQI-Relevant (DLQI-R) is a recently developed scoring that adjusts the total score of the questionnaire for the number of NRRs indicated by a patient. Objectives To compare the discriminatory power of the original and DLQI-R scoring approaches in terms of absolute and relative informativity. Methods Cross-sectional data from 637 patients with morphea, pemphigus and psoriasis were used for the analyses. To assess absolute and relative informativity, Shannon's index and Shannon's evenness index were calculated for the 10 items on the questionnaire and for DLQI and DLQI-R total scores. Results Mean DLQI and DLQI-R scores of patients were 6·13 vs. 6·91. In the subset of patients with NRRs (n = 261, 41%), absolute informativity was higher with the DLQI-R scoring for all eight items with NRR options in all three conditions. The DLQI-R exhibited a better relative informativity in 8, 8 and 6 items in pemphigus, morphea and psoriasis, respectively. The DLQI-R led to an improvement in average item-level informativity in all DLQI score bands up to 20 points. Regarding total scores, the DLQI-R produced both a higher absolute and relative informativity in all three conditions. Conclusions In patients with morphea, pemphigus and psoriasis, DLQI-R scoring improves the discriminatory power of the questionnaire by benefiting from the additional information in NRRs. DLQI-R scoring may be useful both in clinical practice and research. A scoring chart has been developed to aid physicians with scoring. What's already known about this topic? The original scoring of the Dermatology Life Quality Index (DLQI) rates ‘not relevant’ responses as the item of the questionnaire having no impact on the patients’ lives at all. DLQI-Relevant (DLQI-R) is a new scoring developed in 2018 that adjusts the total score of the questionnaire for the number of ‘not relevant’ responses indicated by patients. The discriminatory power of the DLQI-R compared with the DLQI has not yet been investigated. What does this study add? In patients with psoriasis, pemphigus and morphea, DLQI-R scoring improves the discriminatory power of the questionnaire by benefiting from the additional information in ‘not relevant’ responses. What are the clinical implications of this work? DLQI-R scoring may help to more accurately quantify patients’ health-related quality of life both in clinical practice and research. A scoring chart has been developed to aid physicians with scoring.


  • Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines

    by F. Rencz, V. Brodszky, L. Gulácsi, M. Péntek, A.K. Poór, P. Holló, A. Szegedi, É. Remenyik, M. Sárdy, A. Langenbruch, et al.


  • 银屑病中 DLQI 新评分公式的提议

    by F. Rencz, L. Gulácsi, M. Péntek, A. K. Poór, M. Sárdy, P. Holló, A. Szegedi, É. Remenyik, V. Brodszky

  • Proposal of a new scoring formula for the DLQI in psoriasis

    by F. Rencz, L. Gulácsi, M. Péntek, A.K. Poór, M. Sárdy, P. Holló, A. Szegedi, É. Remenyik, V. Brodszky


  • Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis

    by F. Rencz, L. Gulácsi, M. Péntek, A.K. Poór, M. Sárdy, P. Holló, A. Szegedi, É. Remenyik, V. Brodszky

    Background ‘Not relevant’ responses (NRRs) on the Dermatology Life Quality Index (DLQI) may occur in up to 40% of psoriasis patients. As these responses are scored as the item of the questionnaire had no impact on patients’ life at all, it is more difficult for these patients to fulfil the DLQI>10 required by clinical guidelines to become candidates for systemic treatment including biologics. Objectives We propose a new scoring for the DLQI that corrects for the bias in the NRR option and test its construct validity in a sample of psoriasis patients. Methods Data of 242 patients (104 of whom marked at least one NRR) from two earlier cross‐sectional surveys have been reanalysed. For each patient, DLQI score was calculated in two ways: (i) according to the original scoring, and (ii) by applying a new scoring formula (DLQI‐R) that adjusts the total score to the number of NRRs. Construct validity of DLQI‐R was tested against Psoriasis Area and Severity Index (PASI) and EQ‐5D‐3L. Results Mean DLQI and DLQI‐R scores were 9.99±7.52 and 10.98±8.02, respectively. The DLQI‐R allowed eight more patients (3.3%) to achieve the ‘PASI>10 and DLQI>10′ threshold. The results were robust when limiting the maximum number of NRRs allowed to two or three. Compared to the DLQI, DLQI‐R correlated slightly better with PASI (rs=0.585 vs. 0.571) and EQ‐5D‐3L index scores (rs=‐0.580 vs. ‐0.542). Conclusions The DLQI‐R seems to be a valid scoring for avoiding the bias in the NRR option that can help to improve patients’ access to biologics.